

Neuroprotection

Part I: Drugs & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist qualifications. He received graduate training in both Europe and USA and has held academic positions in several countries. He has been involved in biotechnology/pharmaceutical industry since 1989 and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK since 2000. After his retirement from neurosurgery, he is a consultant at Jain PharmaBiotech in Basel, Switzerland.

Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. As associate editor and contributing author of MedLink Neurology (San Diego, California), he is responsible for writing and yearly updating of 160 articles for continuing education of neurologists in an electronic encyclopedia of neurology. He has also written the Textbook of Gene Therapy, which was translated into Chinese, and a book on gene therapy companies published in 2000 by John Wiley & Sons. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer, 2008; 2nd ed 2014) and "Drug Delivery to the Central Nervous System", (Springer/Humana 2010). His recent books include "Handbook of Nanomedicine" (Springer/Humana 2008, Chinese edition by Peking University Press, 2011; 3rd ed Springer 2017), "Drug-induced Neurological Disorders, 3rd ed" (Hogrefe 2011), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2015, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2018, in preparation), and "Applications of Biotechnology in Neurology" (Springer 2013). He has also edited "Applied Neurogenomics" (Springer 2015).

Prof. Jain has been involved in various neuroprotective strategies during his active neurosurgical career including use of hypothermia, hyperbaric oxygen and induced coma. He has a personal experience of methods of neuroprotection used in the care of patients with stroke and CNS trauma as well as during neurosurgical operations.

**April 2018 (first edition published in April 2000)
Copyright © 2018 by:**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	28
1. Introduction	32
Definitions	32
Historical development of neuroprotection	32
Neurophysiological basis of neuroprotection	33
Astrocytic glycogen-derived lactate as fuel for the brain.....	33
Gene expression in the human brain	33
Role of astrocytes in neuroprotection.....	34
Role of glymphatic system in neuroprotection.....	34
Role of sleep in neuroprotection.....	35
Role of cerebral metabolism in neuroprotection	35
Role of circadian genes in neuroprotection	35
Role of blood-brain barrier in neuroprotection.....	36
Role of the gut microbiota in development of integrity of the BBB	36
Intrinsic neuroprotective factors	36
Neuroprotective gene expression	38
<i>Upregulation of GADD34.....</i>	38
<i>Induction of NR4A proteins by CREB in neurons.....</i>	38
<i>Elevation PGC-1α for neuroprotection in PD.....</i>	38
Neurotrophic factors.....	39
Intrinsic nonenzymatic antioxidants	39
Activation of transcription factor Nrf2	39
Intrinsic neuroprotective proteins.....	40
<i>αB-crystallin.....</i>	40
<i>Excitatory amino acid transporters.....</i>	40
<i>Extracellular serine protease thrombin.....</i>	40
<i>Galanin.....</i>	40
<i>Neuroglobin.....</i>	41
<i>Nuclear factor I-A.....</i>	41
<i>Prion protein.....</i>	42
<i>Rai adaptor protein.....</i>	42
Stem cell factor	42
Role of the immune system in neuroprotection	42
Induction of DNA repair enzymes for neuroprotection.....	43
Microtubule-based neuroprotective response to axonal injury	44
Pathomechanisms of CNS injury as basis for neuroprotection	44
Biomarkers of neurological disorders and neuroprotection.....	45
CNS biomarker identification using proteomics	45
Brain imaging for detection of biomarkers.....	46
Neuroprotection in neuroinflammation	46
Biomarkers of neuroinflammation	46
Role of neuroprotection in various neurological disorders	47
Neuroprotection and neuroregeneration.....	48
Acute versus chronic neuroprotection	48
Discovery and evaluation of neuroprotective agents	48
Neuroprotective drug discovery	48
Discovery of CNS drugs that penetrate the blood-brain barrier	49
In vitro assays for the evaluation of neuroprotective agents	49
Oxidative injury model to test neuroprotective drugs.....	50
Apoptosis model for designing neuroprotective drugs	50
Transgenic mouse models of neurological disorders.....	50
Evaluating effects of neuroprotective drugs on living brain slices.....	51
Role of brain imaging in neuroprotective drug discovery and development	51
<i>Positron emission tomography.....</i>	52
<i>Role of single photon emission computed tomography.....</i>	52
<i>Functional CT scanning to evaluate cerebrovascular protection.....</i>	52
<i>Magnetic resonance imaging for the evaluation of neuroprotectives.....</i>	53
Application of nanotechnology to neuroprotection	53
<i>Nanoparticles as neuroprotective antioxidants.....</i>	53
<i>Cadmium telluride nanoparticles prevent Aβ fibril formation.....</i>	54
Evaluation criteria for potential neuroprotective agents.....	55
2. Neuroprotective Agents	56
Classification of neuroprotective agents	56
α2 adrenoceptor agonists	60
Dexmedetomidine	60

Activated protein C	61
Activity-dependent neuroprotective protein	61
Davunetide	61
Adenosine analogs	61
Propentofylline	62
Antidepressants	62
Antidepressant-induced neurogenesis.....	62
Neurogenesis induced by electroconvulsive therapy	63
Neuroprotective effect of selective serotonin reuptake inhibitors	63
Antiepileptic drugs as neuroprotectives	65
BIS-001.....	66
Levetiracetam	66
Phenytoin	66
Valproic acid.....	67
Antiinflammatory agents	67
Aspirin.....	67
Interleukin-1 antagonists.....	68
COX-2 inhibitors	68
<i>Nimesulide</i>	68
Gold microparticles as anti-neuroinflammatory agents.....	69
Minocycline	69
Prostaglandin receptor antagonists.....	70
Anti-apoptosis agents	71
Activated protein C	71
Calpain inhibitors.....	71
Caspase inhibitors.....	72
DNA binding drugs	72
Lithium.....	72
Melatonin.....	73
Olesoxime.....	73
Omega-3 fatty acids.....	73
<i>Docosahexaenoic acid</i>	73
Poly(ADP-ribose) polymerase inhibitors	74
Prevention of apoptosis by binding of proNGF to sortilin.....	75
Antioxidants/free radical scavengers	75
Free radical generation	75
Natural defenses against oxidative stress.....	75
Effects of oxidative damage	76
<i>Oxidative damage and aging</i>	76
<i>Neuronal damage by free radicals</i>	77
<i>Oxidative damage and neurodegenerative disorders</i>	77
Measures to control oxidative stress.....	77
<i>Categories of therapeutic antioxidants</i>	77
<i>Alpha-phenyl-tert-butylNitron</i>	78
<i>Coenzyme Q10</i>	78
<i>Dihydroergocryptine</i>	79
<i>Flavonoids</i>	79
<i>Mitochondria-targeted antioxidants</i>	80
<i>Neuroleptics as antioxidants</i>	80
<i>Nitrones</i>	80
<i>NRF2 for augmenting neuroprotection against oxidative stress</i>	81
Translation of antioxidant neuroprotection from preclinical to clinical.....	81
Carbon monoxide and heme oxygenase	81
Cell transplants	82
Cells secreting neuroprotective substances.....	82
Stem cells.....	82
Stem cell activation for neuroprotection/regeneration by glucocorticoids.....	83
Use of neural stem cells to construct the blood brain barrier.....	83
Cytokines	83
Erythropoietin	83
<i>Non-erythropoietic EPO variants and mimics</i>	85
Granulocyte colony-stimulating factor.....	85
Delta-opioid receptor agonists	86
Delta opioid peptide-induced hibernation for neuroprotection	86
FK960	86
Gene therapy	87
Glucagon-like peptide	87
Glatiramer acetate	88
Glutamate antagonists	88
Neuroprotection by scavenging blood glutamate	89
N-acylethanolamines for protection against glutamatergic excitotoxicity	90

Glutamate transporters.....	90
Glutamate transporter-mediated neuroprotective effect of drugs.....	90
Neuroprotection by targeting KAI subunit of kainate receptor	91
Glycine-proline-glutamate analogs	91
Hydrogen sulfide.....	92
Hibernation induced by hydrogen sulfide.....	92
NMDA receptor ion channel complex.....	92
NMDA receptor antagonists	94
<i>NMDA NR2B subunit receptor antagonists</i>	<i>94</i>
<i>Ifenprodil.....</i>	<i>94</i>
<i>Memantine as a neuroprotective agent</i>	<i>94</i>
<i>NAALADase inhibitors</i>	<i>95</i>
<i>Gacyclidine</i>	<i>95</i>
<i>N-alkylglycines</i>	<i>95</i>
AMPA receptor modulators	95
Metabotropic glutamate receptor modulators.....	96
Cannabinoids.....	96
Dexanabinol	97
Glutathione.....	97
Heat shock proteins	98
Histone deacetylase inhibitors for neuroprotection	98
Hormones	98
Estrogen and neuroprotection.....	98
<i>Neuroprotective effect of estrogen receptor ligands.....</i>	<i>99</i>
<i>Selective estrogen receptor modulators</i>	<i>100</i>
<i>Mitochondrial mechanisms of estrogen neuroprotection</i>	<i>100</i>
Insulin	100
Ion Channel modulators	101
Calcium channel blockers.....	101
<i>Ziconotide.....</i>	<i>102</i>
Na ⁺ channel blockers.....	102
Neuroprotective potassium channel inhibitors	102
Kynurenine inhibitors	103
Leukocyte adhesion inhibitors	103
Modafinil.....	104
Neural regeneration protein	104
Neurite outgrowth-promoting agents	105
Prostaglandin compounds	105
Monoclonal antibodies	105
Neuroimmunophilins.....	105
Cyclosporin-A	106
FK506	106
Rapamycin.....	106
Neurotrophic factors.....	107
Activity-dependent neurotrophic factor	107
Bone morphogenetic proteins	107
Brain-derived neurotrophic factor.....	108
Ciliary neurotrophic factor	108
Fibroblast growth factors	109
Glial cell line-derived neurotrophic factor	109
Insulin-like growth factor.....	110
Nerve growth factor	110
Neurotrophins	111
Osteogenic protein-1	111
Pigment epithelium-derived factor.....	111
Transforming growth factor-β1	112
Vascular endothelial growth factor	112
Neurotrophic factor-related neuroprotective agents.....	112
<i>Amitriptyline as a TrkA and TrkB receptor agonist</i>	<i>112</i>
<i>Colivelin.....</i>	<i>113</i>
<i>Gambogic amide.....</i>	<i>113</i>
<i>Inosine</i>	<i>113</i>
<i>Meteorin</i>	<i>113</i>
<i>Oxygen-regulated protein 150 kD</i>	<i>114</i>
<i>Prosaptide.....</i>	<i>114</i>
<i>Siagoside.....</i>	<i>114</i>
<i>Small molecule activators of the Trk receptors.....</i>	<i>115</i>
Nicotine and nicotinic receptor agonists	115
<i>Neuroprotective effect of galantamine mediated via α7nAChRs</i>	<i>115</i>
<i>Galantamine-induced Aβ clearance via α7nAChRs</i>	<i>116</i>
Nitric oxide-based neuroprotection	116

Nitric oxide synthase inhibitors	117
Nitric oxide mimetics	117
Nitric oxide donating derivatives	117
Nootropics	118
<i>Piracetam</i>	118
Nutraceuticals and naturally-derived compounds	119
Cinnamon	119
Coffee	119
Creatine.....	120
Curcumin/curry	120
<i>Mechanism of neuroprotective effect of curcumin</i>	121
Flavonoids	121
Glyceryltriacetate.....	121
Green tea	121
Herbal preparations.....	122
<i>Flavonoid wogonin</i>	122
<i>Ginseng</i>	122
Nicotinamide	122
Punicalagin from pomegranate	123
Resveratrol	123
Osmotic diuretics	124
Mannitol	124
Osteopontin	124
Oxygen therapeutics.....	125
Oxygen carriers	125
Hemoglobin-based oxygen carriers.....	125
Perfluorocarbons as oxygen carriers	126
Hyperbaric oxygen therapy	127
P7C3 compounds	127
Peptides.....	127
C3-derived peptide for neuroprotection and neuroregeneration.....	127
Corticotropin-releasing hormone.....	128
Thyrotropin-releasing hormone.....	128
Vasoactive intestinal peptide	128
Pharmacological preconditioning.....	129
PPARs as drug targets for neuroprotection.....	129
Proteins	130
Amyloid precursor protein	130
Protein kinase C activators.....	130
Riluzole.....	131
Role of RNA interference in neuroprotection	131
Role of miRNA in neuroprotection.....	131
Sigma receptor agonists as neuroprotective agents	132
SIRT group of proteins.....	132
Statins	133
Steroids	134
Dehydroepiandrosterone.....	134
HF0220	134
Sulforaphane	135
Tauroursodeoxycholic acid	135
Tetanus toxin as a neuroprotective agent.....	135
Thrombolytic agents as neuroprotective agents	135
Uncoupling protein 2	136
Vaccines as neuroprotectives	136
Vitamins as neuroprotective agents.....	136
Vitamin B12	137
Vitamin D	137
Non-pharmacological approaches to neuroprotection.....	137
Caloric restriction.....	138
Cerebral exercise	138
<i>Bilingualism for prevention of decline of mental function</i>	138
Electrical fields for improvement of cerebral function in neurodegeneration	138
Environmental enrichment	139
Hypothermia	139
<i>Limitations of hypothermia</i>	140
<i>Hypothermic neuroprotection in hypoxia-ischemia</i>	140
Ketogenic diet	141
Mediterranean diet.....	141
Nonpharmacological preconditioning for neuroprotection.....	141
Physical exercise.....	142
Suspended animation and neuroprotection.....	143

Transcranial magnetic stimulation	143
3. Neuroprotection in Cerebrovascular Disease	146
Introduction	146
Pathophysiology of cerebral ischemia.....	147
Calcium overload	147
Ion channel dysfunction in stroke.....	148
Role of oxygen free radicals in cerebral ischemia	148
Role of nitric oxide in cerebral ischemia	148
Glutamate as a biomarker of stroke	148
Cerebral edema in stroke.....	149
Gene expression in response to cerebral ischemia.....	149
Induction of heat shock proteins in stroke	149
Role of cytokines and adhesion molecules in stroke	150
<i>Tumor necrosis factor-α</i>	150
<i>Interleukin-1 and IL-6</i>	150
<i>Adhesion molecules</i>	150
DNA damage and repair in cerebral ischemia	150
Role of neurotrophic factors in stroke	151
<i>Problems requiring investigation of the role of NTFs in stroke</i>	151
Role of Poly(ADP-ribose) polymerase (PARP) gene	152
Role of protease-activated receptor 1	152
Reperfusion injury after cerebral ischemia	152
Neuroprotection according to zones in cerebral infarction.....	152
Zone of ischemic infarction.....	152
Penumbra	153
Current management of stroke	154
Neuroprotection in stenosis of intracranial arteries	154
Neuroprotection in stroke with intracerebral hemorrhage	154
Neuroprotection in cerebrovascular malformations	155
<i>Arteriovenous malformations</i>	155
<i>Cavernous cerebrovascular malformations</i>	155
Neuroprotective strategies for ischemic stroke in patients with dementia	156
Neuroprotection in transient ischemic attacks.....	156
Secondary prevention of stroke	156
Neuroprotective therapies for stroke	157
Pharmacologic neuroprotective agents for stroke.....	158
α B-crystallin as a neuroprotectant in stroke	158
Acid-sensing ion channel blockers	158
AMPA receptor antagonists as neuroprotectives for stroke.....	158
<i>Zonampanel</i>	158
Antiapoptotic neuroprotectives	159
<i>NIM811</i>	159
<i>Creatine as neuroprotective in stroke</i>	159
<i>Lithium as a neuroprotective in stroke</i>	159
<i>TUDCA as a neuroprotective in stroke</i>	160
Antiepileptic drugs as neuroprotectives in stroke.....	160
<i>Tiagabine</i>	160
<i>Topiramate</i>	160
<i>Zonisamide</i>	161
Anti-HMGB1 monoclonal antibody	161
Antioxidant approaches	161
<i>Carnosine as a neuroprotective in stroke</i>	162
<i>Dehydroascorbic acid</i>	162
<i>Tocotrienols</i>	162
<i>Uric acid</i>	163
Antiglutamate compounds.....	163
<i>MRZ 2/576</i>	163
<i>L-Phenylalanine</i>	164
Arimocloamol for stroke	164
Cardiac glycosides as neuroprotectives in stroke	164
Clenbuterol	164
Coagulation inhibitors as neuroprotectives	165
<i>Heparin and enoxaparin</i>	165
<i>Warfarin vs dabigatran</i>	165
<i>Apixaban</i>	165
Cox-2 inhibitors for ischemic stroke.....	166
Curcumin as a neuroprotectant in stroke.....	166
Docosahexaenoic acid for ischemic stroke	166
Ephrin-A5 blockers.....	166
Estrogen for stroke	167

Extendin-4	168
Flavones for neuroprotection in stroke	168
<i>Epicatechin</i>	168
<i>Isorhamnetin</i>	169
Granulocyte-macrophage colony-stimulating factor for cerebral ischemia	169
Hamartin induction by cerebral ischemia as a basis for neuroprotection	169
Histone deacetylase inhibitors for neuroprotection in stroke	170
Histamine H ₂ -receptor modulation	170
Inosine for stroke	170
Insulin-like growth factor-I	171
Intravenous immunoglobulin as neuroprotective in stroke	171
Ischemic preconditioning for neuroprotection in stroke	171
Ketone bodies for neuroprotection in stroke	172
Magnesium	172
Mineralocorticoid receptor blockade for neuroprotection	172
miR-223 and neuroprotection in stroke	173
Multifunctional neuroprotective agents	173
NA-1 as neuroprotective against ischemic stroke	173
Nasal delivery of neuroprotective agents in stroke	174
Neuroserpin as a neuroprotective in stroke	174
N-2-mercaptopropionyl glycine	174
NeuroAid	174
Neurotrophic factors as neuroprotectives for stroke	175
<i>Brain-derived neurotrophic factor</i>	175
<i>Fibroblast growth factor</i>	175
<i>G-CSF</i>	176
<i>Glial cell line-derived neurotrophic factor</i>	176
<i>Insulin-like growth factor-1</i>	176
<i>Neuregulin-1</i>	176
NO-based strategies for neuroprotection in cerebral ischemia	177
NOX-4 inhibitors for neuroprotection in stroke	177
Omega-3 fatty acids for neuroprotection after cerebral ischemia-hypoxia	178
Pannexin channel blockers for neuroprotection in stroke	178
Perlecan domain V	178
Peroxisome proliferator-activated receptor- γ agonists	178
PGE ₂ EP2 receptor activation	179
Pioglitazone for reduction of stroke risk	179
Progesterone	179
Propofol as neuroprotective in stroke	179
Proteoglycan-degrading enzymes	180
Proteasome inhibitors	180
Statins for prevention and neuroprotection in stroke	180
Sildenafil	181
Src receptor blockade	181
Stroke vaccine	182
SUN N4057	182
Thrombosis inhibitors	182
<i>Aspirin</i>	182
<i>Clopidogrel</i>	183
<i>Dipyridamole</i>	183
<i>Ticagrelor</i>	183
Vitamin E for neuroprotection in stroke	183
Neuroprotection in ischemia-reperfusion injury	184
Aminoguanidine	184
Dexmedetomidine	185
Methylene blue for neuroprotection in ischemia-reperfusion injury	185
Miscellaneous agents for neuroprotection in reperfusion injury	185
Neuroprotection by treatment of cerebrovascular malformations	185
<i>Arteriovenous malformations</i>	186
<i>Cerebral cavernous malformations</i>	186
Prevention of hemorrhage following ischemic stroke	186
Non-pharmacological neuroprotective therapies for stroke	187
Hypothermia for neuroprotection in acute stroke	187
Hyperbaric oxygen therapy for neuroprotection in acute stroke	187
Hypothermia combination with other neuroprotective strategies	188
Infrared laser therapy for ischemic stroke	189
Preconditioning for neuroprotection against cerebral ischemia	189
Neurosurgical procedures for stroke	190
Neurosurgical procedures for neuroprotection in acute stroke	190
<i>Decompressive hemicraniectomy</i>	190
<i>Thrombectomy</i>	190

<i>Stenting</i>	191
<i>Multiple endovascular modalities</i>	191
Neurosurgical procedures for chronic cerebral ischemia	192
Neurostimulation of sphenopalatine ganglion.....	193
Stent versus surgery for asymptomatic carotid stenosis.....	193
Neurorehabilitation in relation to neuroprotection in stroke.....	193
Protective effect of physical activity on stroke in the elderly	193
Biological therapies for stroke	194
Cell therapy for stroke.....	194
<i>Stem cell transplant for stroke</i>	194
<i>Immortalized cell grafts for stroke</i>	194
<i>Stimulation of intrinsic stem cells for repair of brain in stroke</i>	195
Gene therapy for neuroprotection in cerebrovascular disease	195
Regulation of microRNAs for neuroprotection in cerebral ischemia	197
RNAi-based therapy for neuroprotection in stroke	197
Vaccines for neuroprotection in stroke	197
Neuroprotective therapies for cerebral ischemia: clinical trials	198
Albumin	199
Free radical scavengers	199
DP-b99.....	200
Mildronate.....	201
Minocycline for neuroprotection in stroke	201
Perindopril	201
Failed clinical trials of neuroprotection in stroke.....	201
<i>Ancrod</i>	203
<i>Aptiganel</i>	203
<i>Cerovive</i>	203
<i>Citicoline</i>	204
<i>Desmoteplase</i>	205
<i>Erythropoietin as a neuroprotective in stroke</i>	206
<i>SPD 502</i>	207
<i>Tirilazad mesylate</i>	207
<i>Selfotel</i>	207
<i>Lubeluzole</i>	207
<i>Nalmefene</i>	208
<i>Gavestinel</i>	208
<i>Nimodipine</i>	208
<i>Sipatrigine</i>	208
<i>Causes of failure of stroke trials</i>	209
Measures for prevention of failures in stroke trials	210
Design of acute stroke trial to facilitate drug approval	212
The ideal neuroprotective agent for stroke	212
Prevention of stroke	213
Future of neuroprotection in stroke.....	213
4. Neuroprotection in Traumatic Brain Injury	216
Introduction	216
Cerebral hypoxia/ischemia as a complication of trauma.....	216
Epidemiology of TBI.....	216
TBI in the military	217
Pathophysiology of TBI.....	217
Immediate damage following TBI.....	218
Cerebral edema following TBI	218
Neurometabolic cascade after TBI	219
Delayed damage following TBI.....	219
Mechanism of axonal damage after TBI	220
Role of neuroinflammation in TBI	220
BBB damage after TBI	220
Molecular events following TBI.....	221
Chronic traumatic encephalopathy	221
Neurocognitive sequelae of TBI.....	223
Changes in neurotrophic factors following TBI	223
Changes in neurotransmitters following TBI.....	223
Proteomics of TBI	224
Genetic influences on outcome following TBI	224
Management of TBI	225
Management during acute phase of head injury	225
<i>Control of intracranial pressure and cerebral edema</i>	225
<i>Corticosteroids</i>	226
<i>Decompressive craniectomy</i>	227
Neuroprotection in TBI	227

Amantadine.....	228
Antioxidants	229
Barbiturates	229
β- and γ-secretase inhibitors	229
Beta blockers	229
Bradykinin B ₂ antagonists	230
Cell cycle inhibitors for TBI.....	230
COX-2 inhibitors for neuroprotection in TBI	230
Cyclosporin for neuroprotection in TBI	231
Dexanabiol for TBI	231
Erythropoietin for neuroprotection in TBI	231
Gold implants for neuroprotection in focal TBI	232
Histone deacetylase inhibitors for neuroprotection in TBI	232
KN 38-7271	232
Levosimendan	232
Magnesium sulfate	233
Minocycline for TBI.....	233
Multipotential neuroprotective agents for TBI	233
Nutritional approaches to neuroprotection in TBI.....	233
<i>Branched chain amino acids to ameliorate cognitive impairment in TBI</i>	234
<i>Creatine for neuroprotection in TBI</i>	234
<i>Nicotinamide for neuroprotection in TBI</i>	235
<i>Omega 3 fatty acids as neuroprotectives in TBI</i>	235
Neurotrophic factors for TBI	235
Neurosteroids as neuroprotective agents for TBI	236
NMDA receptor antagonists	237
<i>Neuroprotection in TBI against glutamate-induced excitotoxicity</i>	237
NP-1	238
Nogo-A inhibitor	238
Oxygen carriers for TBI.....	238
Polyethylene glycol for neuroprotection in TBI	239
Propofol for neuroprotection in TBI.....	239
Rapamycin as neuroprotective in TBI.....	239
Simvastatin as neuroprotective in TBI	240
Thyrotropin-releasing hormone analogs	240
Traxoprodil	240
Biological approaches to neuroprotection in TBI	241
Antisense approaches to TBI	241
Cell therapy for TBI.....	241
Gene therapy for TBI.....	241
Vaccines for TBI.....	242
Non-pharmaceutical approaches to neuroprotection in TBI	242
Deep brain stimulation for TBI.....	242
Hyperbaric oxygen therapy for TBI.....	242
Hypothermia	243
Reduction of microglial migration after TBI.....	243
Vacuum for mechanical tissue resuscitation in TBI	243
Prophylactic neuroprotection against TBI.....	243
Role of helmets in protection against TBI	244
Role of physical exercise in protection against TBI	244
Neuroprotection against late sequelae of TBI	244
Antiepileptic drugs for prevention of seizures and neuroprotection	244
Neuroprotection during rehabilitation phase of TBI.....	245
Neuroregeneration following TBI	245
<i>Intrinsic factors that influence regeneration following TBI</i>	245
<i>Causes of lack of regeneration following TBI</i>	246
<i>Approaches to regeneration of the brain following TBI</i>	246
Clinical trials of neuroprotective agents in TBI	247
Ongoing clinical trials in TBI	247
Failed clinical trials in TBI.....	248
<i>Differences between clinical trials and studies in animal models of TBI</i>	249
<i>Subgroup analysis</i>	250
<i>Improving the clinical trial design</i>	250
<i>Clinical trials combining multiple treatment strategies</i>	250
<i>Shortening the trial time</i>	250
Conclusions and future prospects of neuroprotection in TBI.....	251
5. Neuroprotection in Spinal Cord Injury	252
Introduction	252
Pathophysiology of SCI.....	252
<i>Secondary mechanisms of SCI</i>	253

<i>Neurotrophic factor changes in SCI</i>	254
Management of SCI	255
Pharmacological neuroprotective agents for SCI	256
4-aminopyridine	256
Antibodies as neurite growth inhibitors in SCI.....	256
Antiexcitotoxic agents	256
<i>Gacyclidine</i>	256
<i>GM-1 ganglioside</i>	257
Bacterial enzyme chondroitinase ABC	257
Docosahexaenoic acid as neuroprotective in SCI.....	257
Erythropoietin as a neuroprotective in SCI	258
Free radical scavengers for neuroprotection in SCI.....	258
GYKI 52466	258
Immunosuppressants as neuroprotectants in SCI.....	258
Interleukin-10 for neuroprotection in SCI.....	259
Matrix metalloproteinase inhibitors for SCI.....	259
Methylprednisolone	259
Minocycline as neuroprotective in SCI.....	260
Modulation of macrophage responses for neuroprotection after SCI.....	260
Neurotrophic factors for neuroprotection after SCI	261
<i>Promotion of regeneration of neurons in SCI</i>	261
Rho pathway and Rho antagonists in SCI	262
Selenium as a neuroprotective for SCI.....	262
Sialidase for enhancing recovery after SCI	262
Targeting the inflammatory response for neuroprotection in SCI	263
Uric acid as neuroprotective in SCI.....	263
Non-pharmacological approaches to SCI	263
Hyperbaric oxygen therapy	263
Hypothermia for SCI	263
Cell therapy for SCI	264
Autoimmune T cells against CNS myelin-associated peptide	264
Fetal neural grafts for SCI.....	264
Olfactory-ensheathing cells for SCI	264
Oligodendrocyte precursor cells for treatment of SCI.....	265
Schwann cell transplants for SCI.....	265
Transplantation of glial cells for SCI	265
Stem cells for SCI	265
<i>Bone marrow stem cells for SCI</i>	266
<i>Embryonic stem cells for SCI</i>	266
<i>Transplantation of induced pluripotent stem cells in SCI</i>	266
<i>Transplantation of MSCs for SCI</i>	267
<i>Transplantation of NSCs for SCI</i>	267
<i>Transdifferentiation of stem cells into cholinergic neurons for SCI</i>	268
Gene therapy for SCI	268
Combined approaches to spinal cord injury	269
Discovery of new targets for neuroprotective therapies in SCI	270
Clinical trials in SCI	270

6. Neuroprotection in Neurodegenerative Disorders..... 272

Introduction	272
Pathomechanism of neurodegeneration	272
Aging and neurodegeneration.....	272
α -synuclein in neurodegeneration and neuroprotection	273
Dysregulation of cyclin-dependent kinase 5.....	273
Exosomes in CNS neurodegeneration and neuroregeneration.....	273
Genomics of neurodegenerative diseases	274
Impairment of neural transport in neurodegenerative disorders	274
Lack of neurotrophic factors	274
Neuroinflammation in neurodegenerative disorders	275
Neurodegeneration associated with protein misfolding	275
<i>Modulation of neurodegeneration by molecular chaperones</i>	275
<i>Intrabodies targeting protein misfolding in neurodegeneration</i>	276
<i>Targeting proteins aggregation to prevent amyloid formation</i>	276
<i>Tau and neurodegeneration</i>	276
Role of apoptosis in neurodegenerative disorders.....	277
Role of glia in neurodegeneration	277
Role of metals in neurodegeneration	277
Spread of neurodegeneration	278
TDP-43 proteinopathy and neurodegenerative diseases	278
Viral infections and neurodegeneration	278
<i>AIDS and the nervous system</i>	278

<i>Avian influenza as cause of neurodegeneration</i>	279
Neurodegenerative disorders with dementia	280
Dementia with Lewy bodies	280
Frontotemporal dementia	281
Progressive supranuclear palsy	281
Genetic disorders with neurodegeneration	282
Batten disease	282
<i>Cell and gene therapies</i>	282
<i>Cerliponase alfa</i>	283
Familial dysautonomia	283
Friedrich ataxia	283
<i>Pathomechanism of FA</i>	283
<i>Neuroprotection in FA</i>	284
Leigh syndrome	284
Niemann-Pick type C disease	285
Spinal and bulbar muscular atrophy	285
<i>Spinal muscular atrophy</i>	286
Creutzfeldt-Jakob disease	287
Neuroprotection in Creutzfeldt-Jakob disease	287
<i>Pharmacological neuroprotectants against CJD</i>	288
<i>Innovative approaches to neuroprotection in CJD and future prospects</i>	289
Approaches to neuroprotection in neurodegenerative disorders	289
Glutamate-based therapies for neurodegenerative disorders	290
Histone deacetylase inhibitors for neurodegenerative disorders	290
Iron chelation for neuroprotection	290
Mitochondria permeability transition pore complex and neuroprotection	291
Modulation of proteostasis in neurodegenerative disorders	291
7. Neuroprotection in Parkinson Disease	292
Introduction	292
Epidemiology of Parkinson's disease	292
Pathophysiology of Parkinson's disease	292
Alteration of dopamine homeostasis	293
Apoptosis	293
Asynchronous neuronal activity	293
Calcium interaction with α -synuclein	294
Disruption of iron homeostasis	294
Excitotoxicity	294
Genetic factors in PD	294
Oxidative stress	295
Role of neurotrophic factors	296
Role of misfolding proteins	296
Role of α -synuclein in dementia of PD	297
Synaptic vesicle glycoprotein 2C disruption in PD	297
Neuroprotective strategies for PD based on pathomechanism	297
A genetic animal model of PD for testing neuroprotective strategies	298
Aldehyde dehydrogenase 1 protects nigrostriatal dopaminergic neurons	299
RNAi screening to identify neuroprotective genes in a PD model	299
Strategies to stop aggregation of α -synuclein	299
Management of Parkinson's disease	300
Limitation of conventionally administered dopamine therapy	301
Neuroprotective therapy in PD	302
Neuroprotective effect of currently used drugs for PD	302
Pramipexole	302
Rasagiline mesylate	303
Ropinirole	304
Rivastigmine for treatment of dementia and falls associated with PD	304
Selegiline	304
Non-pharmacological strategies for neuroprotection in PD	305
Deep brain stimulation for PD	305
Effect of exercise and environmental enrichment on PD	306
Low-calorie diet in PD	306
Development of neuroprotective therapies for PD	306
2B3-201 for targeted delivery of methylprednisolone	307
9-methyl- β -carboline	307
Adenosine A_{A2} receptor antagonists	307
Antiapoptotic strategies for PD	308
ATP13A2 activation	308
Augmenting CNS glucocerebrosidase activity	308
β 2-Adrenoreceptor agonists	309
Calcium channel blockers for PD	309

Cell therapies for PD.....	309
<i>Stem cells for PD</i>	309
<i>Activation of endogenous stem cells and neural precursors</i>	310
Cogane.....	311
Creatine and minocycline.....	311
Conserved dopamine neurotrophic factor for PD.....	311
Doxycycline as a neuroprotectant in PD.....	312
Free radical scavengers for neuroprotection in Parkinson's disease.....	312
<i>Antioxidants</i>	312
<i>Diapocynin</i>	312
<i>Tea extracts as neuroprotectives</i>	313
Gene therapy for PD.....	313
<i>Implantation of genetically engineered cells</i>	314
<i>Gene therapy using GDNF and neurturin</i>	314
<i>Glutamic acid decarboxylase gene therapy</i>	315
<i>Parkin gene therapy</i>	315
<i>Concluding remarks about gene therapy for PD</i>	316
Heat shock protein 70.....	316
Liver X receptor β agonists.....	316
Melatonin as a neuroprotectant in PD.....	317
Nicotine as a neuroprotective in PD.....	317
Nilotinib for PD.....	317
Neuroprotective effect of leucine-rich repeat kinase-2 inhibitors.....	318
Neuroprotective effect of DJ-1 protein.....	318
Neurotrophic factors.....	318
<i>Basic fibroblast growth factor for PD</i>	319
<i>BDNF for PD</i>	319
<i>GDNF for PD</i>	319
<i>MANF for PD</i>	320
<i>Neurturin for PD</i>	320
<i>Platelet derived growth factor</i>	320
<i>Clinical trials with NTFs</i>	321
Nrf2-mediated neuroprotection in PD.....	321
Nuclear receptor-related 1:Retinoid X receptor α activation.....	321
Omega-3 polyunsaturated fatty acids.....	321
RAB3B overexpression.....	322
RNAi therapy for PD.....	322
Safinamide.....	322
Sirtuin 2 inhibitors for neuroprotection in PD.....	323
Squalamine and PD.....	323
Statins and PD.....	324
Targeting Bax.....	324
Vitamin D for neuroprotection in PD.....	324
Vaccine for PD.....	325
Clinical trials of neuroprotection in Parkinson's disease.....	325
Evaluation of neuroprotective therapies for PD.....	327
Current status and future challenges for neuroprotection in PD.....	328
8. Neuroprotection in Alzheimer Disease.....	330
Introduction.....	330
Pathomechanism of Alzheimer's disease.....	330
Role of glutamate transport dysfunction in AD.....	331
Role of neurotrophic factors in the pathomechanism of AD.....	331
Management of Alzheimer's disease.....	331
Neuroprotection in Alzheimer's disease.....	332
Inhibition of Aβ formation and aggregation.....	333
AN-1792.....	333
Clioquinol.....	334
Colostrinin.....	334
FKBP52 for neuroprotection from Cu toxicity in AD.....	335
Monoclonal antibody m266.....	335
Phenserine.....	335
Secretase inhibitors.....	336
Inhibition of neuroinflammation.....	336
Etanercept.....	336
Neurotrophic factors for neuroprotection in AD.....	337
AL-108.....	337
NGF gene therapy.....	337
Small molecule compounds binding to neurotrophin receptor p75NTR.....	338
Targeting plasminogen activator inhibitor type-1 gene.....	339
Estrogen and AD.....	339

Antioxidants	340
NSAIDS	340
Melatonin for AD	340
Memantine	340
Dimebon	341
Cerebrolysin	342
Curcumin as a neuroprotectant in Alzheimer disease	342
Ginko biloba	342
Tetrahydrocannabinol for neuroprotection in AD	343
Ladostigil tartrate	344
Phosphodiesterase inhibitors as neuroprotectives	344
PPAR-γ agonists	344
Role of statins in reducing the risk of AD	345
Combined therapeutic approaches to AD	345
Clinical trials in AD	345
Future prospects of neuroprotection in AD	354
Mild cognitive impairment	354
Relation of MCI to AD	355
Neuroprotection in MCI	355
<i>Pharmacological approaches for MCI</i>	355
<i>Non-pharmacological approaches to MCI</i>	356
9. Neuroprotection in Huntington Disease	358
Introduction	358
Pathophysiology of HD	358
Management of Huntington's disease	360
Neuroprotection in Huntington's disease	360
Antipsychotic D ₂ and 5-HT _{1A} antagonists	361
Caspase inhibitors.....	361
Clioquinol for HD.....	362
Creatine for stabilizing bioenergetic defects.....	362
Cysteine and neuroprotection in HD	362
<i>Cysteine metabolism reprogramming for neuroprotection in HD</i>	362
<i>Cysteamine</i>	362
Drugs that block inappropriate calcium release from neurons	363
Enhancing protease activity for clearance of mHtt	363
Eicosapentaenoic acid.....	363
Free radical scavengers	364
Histone deacetylase inhibitors	364
Inhibitors of polyglutamine aggregation HD	364
Metal-protein attenuating compounds.....	365
Pridopidine.....	365
RRAS signaling pathway inhibition.....	365
Simvastatin as a neuroprotective in HD	366
Single chain Fv antibodies	366
SIRT1 activators for neuroprotection in HD	366
SIRT2 inhibitors for neuroprotection in HD	367
Synaptic activation of NMDA receptors.....	367
Targeting mutant huntingtin protein.....	367
Tetrabenazine	368
Combinatorial therapy and targeting multiple pathways in HD	368
Cell therapy for HD	369
<i>Cell transplants for HD</i>	369
<i>Stem cell-based therapy for HD</i>	369
Neurotrophic factors and gene therapy	370
RNAi and antisense therapies for Huntington's disease	371
10. Neuroprotection in Amyotrophic Lateral Sclerosis	374
Introduction	374
Pathophysiology of ALS	374
Neuroprotective therapies for ALS	379
Activated protein C	380
AEOL 10150	380
AIMSPRO	380
Anakinra.....	381
Antisense therapy	381
Arimocloamol for ALS.....	381
Ceftriaxone for ALS	382
Coenzyme Q10 for ALS	382
COX-2 inhibitors for ALS	382
Creatine for ALS	383

Dexpramipexole.....	383
Diallyl trisulfide.....	384
Edaravone for ALS	384
Erythropoietin for ALS	384
Gene therapy for ALS	384
Glatiramer acetate	385
GM602	385
Insulin-like growth factor.....	385
Ketogenic diet for neuroprotection in ALS.....	386
Lenalidomide.....	386
Lithium for neuroprotection in ALS	387
Masitinib	387
Melatonin for ALS.....	387
Methylcobalamin.....	388
Minocycline for ALS	388
Olesoxime as neuroprotective for ALS.....	388
ONO-2506 for ALS	388
Riluzole	389
RNAi-based therapy for ALS	389
Sodium phenylbutyrate.....	389
Stem cell therapy.....	390
<i>Clinical applications</i>	390
<i>Stem cell-based drug discovery for ALS</i>	390
<i>Suppressors of mTDP-43 toxicity</i>	391
Talampanel	391
Tamoxifen.....	392
Vaccination for ALS caused by SOD1 mutations	392
Vascular endothelial growth factor for ALS	392
Vitamin E for ALS.....	393
Clinical trials of neuroprotective therapies for ALS	393
Concluding remarks and future prospects.....	396
Use of CRISPR/Cas9 technology to find new targets in ALS	396

11. Neuroprotection in Miscellaneous Neurological Disorders 398

Introduction	398
Neuroprotection in synaptopathies.....	398
Neuroprotection in ASD	399
Neuroprotection in fragile X syndrome.....	399
Neuroprotection in dementia	399
Age-related dementia	399
<i>Aging brain and oxidative stress</i>	400
<i>Enhancing endogenous neurotrophic support of the aging brain</i>	400
<i>Hsp70 and age-related neurodegeneration</i>	401
<i>Pharmacological approaches for treatment of age-related dementia</i>	401
<i>Physical exercise to prevent decline of mental function with aging</i>	402
Vascular dementia	402
<i>Prediction of dementia in persons with vascular risk factors</i>	403
<i>Management of subcortical vascular dementia</i>	403
Dementia with Lewy bodies.....	404
Neuroprotection in AIDS dementia	404
Multiple system atrophy	405
Epilepsy	406
Mechanisms of neuronal damage in epilepsy	406
Strategies for neuroprotection in epilepsy	407
AEDs and neuroprotection.....	407
Cell therapy for neuroprotection in epilepsy.....	408
<i>Cell therapy of posttraumatic epilepsy</i>	409
<i>Cell therapy for temporal lobe epilepsy</i>	409
<i>Cell therapy for pharmaco-resistant epilepsies</i>	410
Drugs targeting mossy cells in drug-resistant epilepsy.....	410
Gene therapy for neuroprotection in epilepsy	410
Hyaluronan-based preservation of brain ECS volume.....	411
Hypothermia for neuroprotection in status epilepticus.....	411
Ketogenic diet for prevention of seizures.....	412
miR-211 as an attenuator of cholinergic-mediated seizures	412
Multiple sclerosis	412
Introduction	412
Epidemiology of multiple sclerosis	412
Pathophysiology	413
Current management of multiple sclerosis.....	413
Specific therapies for MS based on pathomechanism	414

Neuroprotection in multiple sclerosis	415
Clinical trials of neuroprotective therapies for MS	416
Neuroprotection by control of progressive forms of multiple sclerosis	417
Neuroprotection by controlling autoimmune inflammation in the brain	417
Neuroprotection by sealing the BBB with imatinib	418
TRPM4 cation channel blockers	418
Remyelination for neuroprotection in multiple sclerosis	418
Agents for neuroprotection in multiple sclerosis	419
<i>Angiotensin-II inhibitors</i>	419
<i>Antiglutamate agents</i>	419
<i>Antioxidants for neuroprotection in MS</i>	419
<i>Antisense and RNAi approaches to MS</i>	419
<i>B cell depletion therapy</i>	420
<i>Cell therapy for multiple sclerosis</i>	420
<i>Cannabinoids for neuroprotection in MS</i>	423
<i>Cladribine</i>	423
<i>Curcumin as a neuroprotectant in multiple sclerosis</i>	424
<i>Cytokine-directed therapies in MS</i>	424
<i>Dalfampridine in MS</i>	424
<i>Dimethyl fumarate</i>	425
<i>DNA vaccine for MS</i>	425
<i>Erythropoietin as a neuroprotective in MS</i>	425
<i>Fingolimod</i>	426
<i>Fusokine composed of GM-CSF and IL-15 for immune suppression</i>	427
<i>Gene therapy for MS</i>	427
<i>Ibudilast for MS</i>	427
<i>Iron chelators</i>	427
<i>IVIG for MS</i>	428
<i>Kinase inhibitors</i>	428
<i>Laquinimod</i>	428
<i>Melatonin for MS</i>	429
<i>Minocycline for MS</i>	429
<i>Monoclonal antibodies for MS</i>	429
<i>Natalizumab</i>	430
<i>Natural human antibodies for repair of myelin</i>	431
<i>Neurotrophic factors for multiple sclerosis</i>	431
<i>Nimodipine</i>	432
<i>Oral immunomodulatory agents for MS</i>	432
<i>Protein kinase Cβ as a therapeutic target for stabilizing BBB in MS</i>	432
<i>Recombinant T-cell ligands</i>	433
<i>Statins for MS</i>	433
<i>Teriflunomide</i>	433
<i>Tolerance-directed immunotherapy for MS</i>	434
Concluding remarks and future prospects for neuroprotection in MS	434
Neuroprotection in anti-NMDA receptor encephalitis	435
Neuroprotection in transverse myelitis.....	435
Neuroprotection in decompression sickness	436
Neuroprotection in victims of drowning	437
Neuroprotection in CSF circulatory disorders.....	437
Neuroprotection in hydrocephalus	437
Neuroprotection in normal pressure hydrocephalus	438
Neuroprotection in infections of the CNS	438
Neuroprotection in bacterial meningitis	439
<i>Mechanism of neural injury in bacterial meningitis</i>	439
<i>Strategies for neuroprotection</i>	439
Neuroprotection in cryptococcal meningitis.....	440
Neuroprotective approach to rabies.....	440
Neuroprotection in cerebral malaria.....	440
Neuroprotection in complications of systemic disorders.....	441
Neurological complications of cardiovascular disorders.....	441
<i>Neuroprotection after myocardial infarction</i>	441
<i>Neuroprotection in hypertensive encephalopathy</i>	441
<i>Management of hypertension to prevent dementia</i>	442
Neuroprotection in complications of diabetes	442
<i>Neuroprotection in hypoglycemic coma</i>	442
<i>Neuroprotection in diabetic retinopathy</i>	443
Neurological complications of liver disorders.....	444
<i>Hepatic encephalopathy</i>	444
<i>Bilirubin encephalopathy</i>	445
Neuroprotection in neurological complications of renal disease.	446
Neuroprotection in toxic encephalopathies.....	446

Encephalopathy due to organophosphorus poisoning	446
Neuroprotection against chemotherapy-induced brain damage	447
Neuroprotection against alcohol	447
<i>Alcoholic neurologic disorders</i>	447
<i>Fetal alcohol syndrome</i>	448
<i>Pathogenesis of alcohol-induced damage to the nervous system</i>	448
<i>Neuroprotection against neurotoxicity of alcohol</i>	448
Neuroprotection against exposure to therapeutic radiation	449
Neuroprotection against radiation encephalopathy	449
Role of SOD in protection against radiation-induced hippocampal dysfunction	450
Catalase reduces mitochondrial ROS for neuroprotection from proton irradiation	450
Neuroprotection in hypoxia-ischemia	450
Neuroprotection of the fetus and the neonate	450
Neuroprotection in preterm babies	451
Neuroprotection in neonatal hypoxic-ischemic brain injury	451
<i>Pathomechanism of neonatal hypoxic-ischemic brain injury</i>	451
<i>Management of neonatal hypoxia-ischemia</i>	452
<i>Approaches to neuroprotection in neonatal hypoxia-ischemia</i>	452
<i>Hyperbaric oxygen for neonatal hypoxia-ischemia</i>	453
<i>Hypothermia for neonatal hypoxia-ischemia</i>	453
<i>Melatonin for neonatal hypoxia-ischemia</i>	453
<i>Minocycline for neonatal hypoxia-ischemia</i>	453
<i>Nicotinamide mononucleotide adenylyl transferase 1</i>	454
<i>Nitric oxide inhalation for neonatal hypoxia-ischemia</i>	454
<i>Plasminogen activator inhibitor-1 for neonatal hypoxia-ischemia</i>	454
<i>Recombinant erythropoietin for neonatal hypoxia-ischemia</i>	454
Neuroprotection in carbon monoxide poisoning	455
Pathomechanism of CO poisoning as a basis for neuroprotection	455
Management of CO poisoning	456
Neuroprotection after cardiac arrest	456
Neuroprotection in delayed post-hypoxic leukoencephalopathy	457
Neuroprotection in sleep apnea	457
Neuroprotection in mitochondrial dysfunction	458
Mitochondrial permeability transition	458
Mitochondrial approaches for neuroprotection	459
Methylene blue	460
Role of nanolasers in evaluation of mitochondrial neuroprotectants	460
Neuroprotection in mitochondrial encephalopathies	460
Neuroprotection in psychiatric disorders	461
Cognitive impairment in schizophrenia	461
Electroconvulsive therapy and neuroprotection	461
Neuroprotection in schizophrenia	462
Neuroplasticity and neuroprotection in stress-induced psychiatric disorders	462
Neuroprotection in hearing loss	462
Causes of hearing loss	463
Pathomechanism of hearing loss	463
Prevention and treatment of hearing loss	464
<i>Hyperbaric oxygen for hearing loss</i>	464
<i>Stem cell therapy for hearing loss</i>	464
<i>Auditory hair cell replacement by gene therapy</i>	465
<i>Pharmaceutical approaches to hearing loss</i>	465
Neuroprotection of peripheral nerves	467
Neuroprotective agents for peripheral nerves	467
<i>Acetyl-L-carnitine for peripheral nerve injuries</i>	467
<i>Atorvastatin for peripheral nerve injuries</i>	467
<i>Erythropoietin for neuroprotection in peripheral nerve injuries</i>	468
Neuroprotection in peripheral nerve injuries	468
<i>Role of hyperbaric oxygen in peripheral nerve injuries</i>	468
<i>Role of neurotrophic factors in peripheral nerve injuries</i>	469
<i>Pharmacological approaches to Schwann cells</i>	469
<i>Role of gene therapy in neuroprotection of injured peripheral nerves</i>	469
<i>Schwann cell transplantation for peripheral nerve injury</i>	469
<i>Targeting Wallerian degeneration slow protein for neuroprotection</i>	470
Peripheral neuropathy	470
<i>Neuroprotection in diabetic neuropathy</i>	470
<i>Cell therapy for neuroprotection in diabetic neuropathy</i>	471
<i>Gene therapy with zinc finger DNA-binding proteins</i>	471
<i>Neuroprotection in chemotherapy-induced neuropathy</i>	471
Chronic inflammatory demyelinating polyradiculoneuropathy	472
<i>Neuroprotection in CIDP</i>	472

12. Neuroprotection of the Optic nerve and the Retina	474
Introduction	474
Optic neuropathy	474
Pathophysiology	474
Neuroprotection in optic neuritis	475
<i>Evaluating efficacy of drugs for optic neuritis.....</i>	<i>476</i>
<i>Flupirtine</i>	<i>476</i>
<i>Sodium channel blockers</i>	<i>477</i>
<i>Resveratrol</i>	<i>477</i>
Neuroprotection in optic nerve trauma	477
Potential regeneration of the optic nerve.....	478
Subthreshold transpupillary thermotherapy for protection of RGCs.....	478
Neuroprotection of optic nerve in glaucoma	478
Aminoguanidine as a neuroprotective in glaucoma	480
Antiglutamate agents for neuroprotection of optic nerve	480
Betaxolol	480
NGF eye drops.....	480
Targeting A β in glaucoma treatment.....	481
TNF- α blockers for neuroprotection in glaucoma	481
Concluding remarks about neuroprotection in glaucoma.....	481
Neuroprotection in retinal ischemia.....	481
β -adrenoceptor antagonists.....	482
Brimonidine as a neuroprotective in ischemic retinopathy.....	482
Endogenous neuroprotection in the retina	483
Erythropoietin for neuroprotection of retinal ischemia.....	483
Gene therapy for retinal neuroprotection.....	483
Hyperbaric oxygen for central retinal artery occlusion.....	484
Levodopa for treating non-arteritic anterior ischemic optic neuropathy	484
Thioredoxin as a neuroprotective agent in retinal ischemia.....	484
Protection against oxygen-induced retinopathy	484
Neuroprotection in macular degeneration	485
Epidemiology.....	485
Pathomechanism of AMD	485
Current treatment of AMD	485
Novel neuroprotective strategies against retinal degeneration	487
Antiangiogenic agents	488
Humanized MAb against A β	488
LXR agonists	489
Neurotrophic factors for neuroprotection in AMD	489
<i>CNTF for neuroprotection in AMD</i>	<i>489</i>
<i>N-acetylserotonin derivatives</i>	<i>489</i>
Nutritional protection against AMD	489
Progestogenic hormones.....	490
Protection of retinal cells from oxidative-stress-induced apoptosis.....	490
Sulindac	490
Tandospirone	491
Cell therapy for macular degeneration	491
<i>Retinal pigment epithelial cells.....</i>	<i>491</i>
<i>Stem cells.....</i>	<i>491</i>
<i>Neural progenitor cells.....</i>	<i>491</i>
Gene therapy for retinal degeneration	492
RNAi-based treatments for AMD.....	492
Neuroprotection in proliferative diabetic retinopathy	493
RNAi-based approaches to diabetic retinopathy.....	493
Clinical trials for optic nerve and retinal neuroprotection	494
13. Neuroprotection during Anesthesia and Surgery	496
Introduction	496
Anesthetic agents as neuroprotectives	496
Barbiturates	496
<i>Thiopental.....</i>	<i>497</i>
Etomidate	498
Propofol.....	498
Ketamine	498
Gaseous anesthetics.....	499
<i>Isoflurane</i>	<i>499</i>
<i>Xenon.....</i>	<i>499</i>
Local anesthetics	500
Monitoring of CNS function during anesthesia and surgery	500
Monitoring of cerebral function	500
Monitoring of spinal cord function during spinal surgery	500

Perioperative neuroprotection	501
Neuroprotection during cardiovascular procedures	502
CNS complications of cardiac surgery	502
Neuroprotective strategies during cardiac surgery	503
<i>Neuroprotection before anticipated or induced cardiac arrest.....</i>	<i>504</i>
<i>Neuroprotection during coronary artery bypass grafting.....</i>	<i>504</i>
<i>Preconditioning with hyperbaric oxygen.....</i>	<i>505</i>
<i>Neuroprotection in aortic surgery.....</i>	<i>505</i>
<i>Pharmacologic strategies for neuroprotection in aortic surgery.....</i>	<i>506</i>
Cerebral protection during organ transplantation surgery	506
Cerebral protection during neurosurgery	507
Cerebral angiography and endovascular surgery	507
Cerebral protection during surgery for arteriovenous malformations	507
Cerebral protection during surgery of intracranial aneurysms	507
Management of subarachnoid hemorrhage	508
<i>Vasospasm associated with subarachnoid hemorrhage.....</i>	<i>508</i>
Cerebral protection during carotid endarterectomy.....	510
Cerebral protection during surgery of brain tumors	510
Neuroprotective measures prior to surgery.....	511
<i>HBO preconditioning for neuroprotection during surgery</i>	<i>511</i>
Neuroprotection following surgery	511
<i>Neuroprotection by cranioplasty after decompressive craniectomy</i>	<i>512</i>
14. Markets for Neuroprotective Therapies.....	514
Introduction	514
The financial burden of CNS damage	514
Markets for neuroprotective therapies.....	514
Markets according to therapeutic areas.....	514
<i>Stroke</i>	<i>515</i>
<i>CNS injury</i>	<i>515</i>
<i>Alzheimer disease</i>	<i>516</i>
<i>Parkinson disease</i>	<i>516</i>
<i>Multiple sclerosis.....</i>	<i>516</i>
<i>Epilepsy.....</i>	<i>516</i>
Values of neuroprotective therapies in major world markets.....	516
Unmet needs in neuroprotectives.....	517
Future of neuroprotective therapies	518
Challenges in neuroprotective drug development	518
Promising areas of research in neuroprotection.....	519
<i>Autoreactive antibodies</i>	<i>519</i>
<i>Biological therapies for neuroprotection</i>	<i>519</i>
<i>Multidisciplinary approaches to neuroprotection</i>	<i>520</i>
15. References.....	522

Tables

Table 1-1: Historical landmarks in the development of neuroprotection	32
Table 1-2: Intrinsic neuroprotective factors.....	37
Table 1-3: Common features of pathophysiology of brain damage in diseases	45
Table 1-4: Place of neuroprotection in management of CNS disorders	47
Table 1-5: Indications for the use of neuroprotection	47
Table 1-6: Neuroprotective nanoparticles.....	53
Table 2-1: A classification of neuroprotective agents	56
Table 2-2: The neuroprotective effect of antiepileptic drugs	65
Table 2-3: Neuroprotective affect of minocycline in animal models.....	70
Table 2-4: Classification of antioxidants or free radical scavengers with neuroprotective potential.....	78
Table 2-5: Role of erythropoietin in the nervous system	83
Table 2-6: Ionotropic glutamate receptors	89
Table 2-7: Classification of metabotropic glutamate receptors (mGluRs).....	89
Table 2-8: Methods for neuroprotection based on nonpharmacological preconditioning	141
Table 3-1: Cerebrovascular diseases that are relevant to neuroprotection.....	146
Table 3-2: Neuroprotective strategies for stroke	157
Table 3-3: Selected effective combinations of hypothermia with other neuroprotective strategies for the treatment of ischemic stroke in experimental models	188
Table 3-4: Neuroprotective gene transfer in models of cerebral ischemia	195
Table 3-5: Neuroprotective gene therapy in animal stroke models	196
Table 3-6: Neuroprotective agents in clinical development for acute cerebrovascular disease	198
Table 3-7: Some failed trials for neuroprotective therapy for stroke	201

Table 3-8: Preclinical assessment of neuroprotective agents in acute stroke models.....	210
Table 3-9: Stroke prevention based on control of risk factors	213
Table 4-1: Classification of closed TBI	216
Table 4-2: Current conventional management of traumatic brain injury	225
Table 4-3: Neuroprotective strategies for traumatic brain injury	227
Table 4-4: Intrinsic factors that influence regeneration in the central nervous system	245
Table 4-5: A classification of approaches to regeneration of the brain following injury	246
Table 4-6: Ongoing or completed clinical trials for neuroprotection in TBI	248
Table 4-7: Discontinued or failed clinical trials for neuroprotection in TBI.....	249
Table 5-1: Secondary mechanisms in spinal cord injury.....	254
Table 5-2: Neuroprotective and regenerative approaches for SCI.....	255
Table 5-3: Clinical trials for neuroprotection in SCI	270
Table 6-1: Neurodegenerative disorders with dementia	280
Table 6-2: Drugs in clinical trials for spinal muscular atrophy	286
Table 6-3: Approaches to neuroprotection in CJD.....	288
Table 6-4: Glutamate-based therapies in clinical development for neurodegenerative disorders.....	290
Table 7-1: Prevalence of Parkinson's disease in major markets 2016-2026	292
Table 7-2: Factors in the etiology of Parkinson's disease.....	292
Table 7-3: Strategies for the treatment of Parkinson's disease	300
Table 7-4: Gene therapy techniques applicable to Parkinson disease	313
Table 7-5: Current clinical trials of neuroprotective therapies for Parkinson disease	325
Table 7-6: Failed clinical trials of neuroprotective therapies for Parkinson disease.....	326
Table 7-7: Evaluation of neuroprotective agents for PD	327
Table 8-1: Cholinergic approaches to the treatment of Alzheimer's disease	332
Table 8-2: Neuroprotective agents for Alzheimer's disease.....	332
Table 8-3: Clinical trials for neuroprotection in Alzheimer disease	345
Table 8-4: Discontinued, failed or inconclusive clinical trials of Alzheimer disease	351
Table 8-5: Strategies for discovery of neuroprotective therapies for AD	354
Table 9-1: Neuroprotective approaches in HD.....	360
Table 10-1: Hypotheses for the pathogenesis of amyotrophic lateral sclerosis	374
Table 10-2: Genetic diagnostic biomarkers of ALS.....	377
Table 10-3: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	379
Table 10-4: Clinical trials of neuroprotective therapies for ALS	393
Table 10-5: Failed or discontinued trials of neuroprotective therapies for ALS.....	394
Table 11-1: Therapeutic approaches to subcortical vascular dementia	403
Table 11-2: Measures for neuroprotection against the sequelae of seizures	407
Table 11-3: Neuroprotective effect of AEDs in animal models of status epilepticus (SE)	408
Table 11-4: Specific therapies for MS based on postulated pathomechanisms.....	414
Table 11-5: Approved neuroprotective therapies for multiple sclerosis.....	415
Table 11-6: Neuroprotective therapies for multiple sclerosis in clinical trials.....	416
Table 11-7: Measures to prevent acute bilirubin encephalopathy	445
Table 11-8: Approaches to neuroprotection in neonatal hypoxia-ischemia.....	452
Table 11-9: Drugs with neuroprotective effect at mitochondrial level.....	459
Table 11-10: Causes of sensorineural hearing impairment	463
Table 11-11: Strategies for prevention and treatment of sensorineural hearing loss.....	464
Table 11-12: Agents for neuroprotection of the peripheral nervous system	467
Table 12-1: Causes of optic neuropathy.....	474
Table 12-2: Clinical trials of neuroprotective therapies in optic neuritis	476
Table 12-3: Neuroprotection of the optic nerve in glaucoma	479
Table 12-4: Strategies for neuroprotection in retinal ischemia	482
Table 12-5: Novel neuroprotective strategies against retinal degeneration	487
Table 12-6: Clinical trials for retinal neuroprotection	494
Table 13-1: CNS complications associated with cardiac procedures	502
Table 13-2: Strategies for protection of the brain during cardiac surgery	503
Table 13-3: Medical and surgical methods of cerebral vasospasm management.....	509
Table 13-4: Neuroprotection by prevention of vasospasm	509
Table 14-1: Neuroprotective market values 2017-2027	515
Table 14-2: Values of neuroprotective therapies in major world markets from 2017-26	516

Figures

Figure 2-1: Mechanism of neuroprotective effect of sigma-1 receptor agonists	64
Figure 2-2: NMDA receptor ion channel complex.....	93
Figure 2-3: Neuroprotective effect of galantamine	116
Figure 3-1: Some steps in the ischemic cascade and site of action of neuroprotectives	147
Figure 3-2: Relationship between dementia and acute ischemic stroke	156
Figure 3-3: A roadmap for neuroprotection	211
Figure 4-1: Cascade of events following traumatic brain injury	218
Figure 4-2: Neurometabolic cascade of mild TBI	219
Figure 4-3: Secondary injury mechanisms after TBI	220

Figure 4-4: Management of raised ICP after TBI	226
Figure 5-1: Pathomechanism of acute spinal cord injury	253
Figure 7-1: Neuroprotective strategies against death of dopamine-containing neurons in PD	298
Figure 9-1: Role of HTT protein in pathogenesis of HD and points of intervention.....	368
Figure 9-2: Antisense therapeutic approaches to HD for lowering huntingtin	372
Figure 11-1: A schematic overview of synaptopathies.....	398
Figure 11-2: Common mechanisms of neural damage in cerebral ischemia and seizures	406
Figure 11-3: Role of neuroprotection in epilepsy and its treatment.....	407
Figure 11-4: Mechanisms of neonatal hypoxia-ischemia and targets for neuroprotection.....	452
Figure 14-1: Unmet therapeutic needs in neuroprotective therapies	518